Haloalkyl ester derivatives of coumarin for the treatment of coagulation disorders
View Patent ↗The subject invention provides anticoagulant compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R 1 , R 3 , n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The invention further comprises pharmaceutical compositions comprising the compounds and salts of the invention, as well as methods of using the compounds, salts, and compositions of the invention.
1. A method of treating a coagulation disorder comprising administering to a patient in need of anticoagulation therapy an effective amount of a composition comprising a compound according to Formula VI:
or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient wherein
R is C 1 -C 8 alkyl substituted with at least one halogen, wherein said halogen is fluoro.
2. A method according to claim 1 , wherein
R is C 3 -C 7 alkyl substituted with at least one halogen, wherein said halogen is fluoro.
3. A method according to claim 1 , wherein
R is C 3 -C 6 alkyl substituted with at least one halogen, wherein said halogen is fluoro.
4. A method according to claim 1 , wherein
R is C 3 -C 6 alkyl substituted with at least two halogens, wherein each said halogen is fluoro.
5. A method according to claim 1 , wherein
R is C 3 -C 6 alkyl substituted with at least six halogens, wherein each said halogen is fluoro.
6. A method according to claim 1 , wherein
R is
7. A method according to claim 1 , wherein the compound is 1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)benzoate, or pharmaceutically acceptable salts thereof.
8. A method according to claim 1 , wherein the coagulation disorder is selected from the group consisting of venous thrombosis, pulmonary embolism, thromboembolic complications associated with atrial fibrillation, and thromboembolic complications associated with cardiac valve replacement.
9. A method according to claim 6 , wherein the coagulation disorder is selected from the group consisting of venous thrombosis, pulmonary embolism, thromboembolic complications associated with atrial fibrillation, and thromboembolic complications associated with cardiac valve replacement.
10. A method of inhibiting vitamin K epoxide reductase comprising administering to an individual an effective amount of a composition comprising a compound according to Formula VI:
or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient wherein
R is C 1 -C 8 alkyl substituted with at least one halogen, wherein said halogen is fluoro.
11. A method according to claim 10 , wherein
R is C 3 -C 7 substituted with at least one halogen, wherein said halogen is fluoro.
12. A method according to claim 10 , wherein
R is C 3 -C 6 alkyl substituted with at least one halogen, wherein said halogen is fluoro.
13. A method according to claim 10 , wherein
R is C 3 -C 6 alkyl substituted with at least two halogens, wherein each said halogen is fluoro.
14. A method according to claim 10 , wherein
R is C 3 -C 6 alkyl substituted with at least six halogens, wherein each said halogen is fluoro.
15. A method according to claim 10 , wherein
R is
16. A method according to claim 10 , wherein the compound according to Formula VI is 1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)benzoate, or pharmaceutically acceptable salts thereof.
17. A method of inhibiting clotting factor synthesis comprising administering to an individual an effective amount of a composition comprising a compound according to Formula VI:
or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient wherein
R is C 1 -C 8 alkyl substituted with at least one halogen, wherein said halogen is fluoro.
18. A method according to claim 17 , wherein
R is C 3 -C 7 alkyl substituted with at least one halogen, wherein said halogen is fluoro.
19. A method according to claim 17 , wherein
R is C 3 -C 6 alkyl substituted with at least one halogen, wherein each said halogen is fluoro.
20. A method according to claim 17 , wherein
R is C 3 -C 6 alkyl substituted with at least two halogens, wherein each said halogen is fluoro.
21. A method according to claim 17 , wherein
R is C 3 -C 6 alkyl substituted with at least six halogens, wherein each said halogen is fluoro.
22. A method according to claim 17 , wherein
R is
23. A method according to claim 17 , wherein the compound according to Formula VI is 1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)benzoate, or pharmaceutically acceptable salts thereof.
24. A method according to claim 17 , wherein the clotting factors are one or more of Factor II, Factor VI, Factor IX, Factor X, protein C and protein S.
25. A method according to claim 23 , wherein the clotting factors are one or more of Factor II, Factor VII, Factor IX, Factor X, protein C and protein S.